OJOG  Vol.5 No.12 , October 2015
Immunohistochemical Analysis of p16 Expression in Uterine Smooth Muscle Tumors
ABSTRACT
Objective: Immunohistochemistry with p16 antibody is used as a diagnostic marker in several gynecologic pathologies. The purpose of the present study was to evaluate the diagnostic and prognostic significance of p16 immunohistochemistry in various uterine smooth muscle tumors. Methods: Tissue specimens, including 29 leiomyomas, 13 smooth muscle tumors of uncertain malignant potential (STUMP), and 17 leiomyosarcomas, were obtained from 59 patients with uterine smooth muscle tumors. The prevalence of p16 expression in various uterine smooth muscle tumors was examined using immunohistochemistry methods and we investigated the association between p16 expression and various clinicopathologic parameters, including prognosis of leiomyosarcomas. Results: The prevalence of p16 expression of leiomyomas, STUMP, and leiomyosarcomas tumors was 10.3%, 38.4%, and 76.4%, respectively. The prevalence and immunohistochemistry scores of p16 were significantly higher in the leiomyosarcomas group than in the leiomyomas or STUMP tumor groups. In the leiomyosarcomas groups, p16 immunohistochemistry scores were significantly higher in the groups with more advanced stage, higher mitotic activity, and recurrence. The relationship among p16 immunohistochemistry scores and age, tumor size, extent of necrosis, and degree of myometrial invasion was not significant. High expression of p16 in leiomyosarcomas was linked to shorter disease-free and overall survival. Conclusions: The use of p16 immunohisitochemistry is a useful marker in differential diagnosis in various uterine smooth muscle tumors. Moreover, p16 overexpression possibly plays an important role in tumor progression and we demonstrate that p16 may be a predictor of overall survival in patients with leiomyosarcoma tumors.

Cite this paper
Kanayama, S. , Oi, H. , Kawaguchi, R. , Furukawa, N. and Kobayashi, H. (2015) Immunohistochemical Analysis of p16 Expression in Uterine Smooth Muscle Tumors. Open Journal of Obstetrics and Gynecology, 5, 688-697. doi: 10.4236/ojog.2015.512097.
References
[1]   Zagouri, F., Dimopoulos, A.M., Fotiou, S., Kouloulias, V. and Papadimitriou, C.A. (2009) Treatment of Early Uterine Sarcomas: Disentangling Adjuvant Modalities. World Journal of Surgical Oncology, 7, 38.
http://dx.doi.org/10.1186/1477-7819-7-38

[2]   Ip, P.P. and Cheung, A.N. (2011) Pathology of Uterine Leiomyosarcomas and Smooth Muscle Tumours of Uncertain Malignant Potential. Best Practice & Research Clinical Obstetrics & Gynaecology, 25, 691-704.
http://dx.doi.org/10.1016/j.bpobgyn.2011.07.003

[3]   Sabah, M., Cummins, R., Leader, M. and Kay, E. (2005) Leiomyosarcoma and Malignant Fibrous Histiocytoma Share Similar Allelic Imbalance Pattern at 9p. Virchows Archiv, 446, 51-58.
http://dx.doi.org/10.1007/s00428-004-1190-2

[4]   Mittal, K. and Demopoulos, R.I. (2001) MIB-1 (Ki-67), p53, Estrogen Receptor, and Progesterone Receptor Expression in Uterine Smooth Muscle Tumors. Human Pathology, 32, 984-987.
http://dx.doi.org/10.1053/hupa.2001.27113

[5]   Leiser, A.L., Anderson, S.E., Nonaka, D., Chuai, S., Olshen, A.B., Chi, D.S., et al. (2006) Apoptotic and Cell Cycle Regulatory Markers in Uterine Leiomyosarcoma. Gynecologic Oncology, 101, 86-91.
http://dx.doi.org/10.1016/j.ygyno.2005.09.055

[6]   Hewedi, I.H., Radwan, N.A. and Shash, L.S. (2012) Diagnostic Value of Progesterone Receptor and p53 Expression in Uterine Smooth Muscle Tumors. Diagnostic Pathology, 7, 1.
http://dx.doi.org/10.1186/1746-1596-7-1

[7]   Kamb, A., Gruis, N.A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S.V., et al. (1994) A Cell Cycle Regulator Potentially Involved in Genesis of Many Tumor Types. Science, 264, 436-440.
http://dx.doi.org/10.1126/science.8153634

[8]   Kim, W.Y. and Sharpless, N.E. (2006) The Regulation of INK4/ARF in Cancer and Aging. Cell, 127, 265-275.
http://dx.doi.org/10.1016/j.cell.2006.10.003

[9]   Kratzke, R.A., Greatens, T.M., Rubins, J.B., Maddaus, M.A., Niewoehner, D.E., Niehans, G.A., et al. (1996) Rb and p16INK4a Expression in Resected Non-Small Cell Lung Tumors. Cancer Research, 56, 3415-3420.

[10]   Caldas, C., Hahn, S.A., da Costa, L.T., Redston, M.S., Schutte, M., Seymour, A.B., et al. (1994) Frequent Somatic Mutations and Homozygous Deletions of the p16 (MTS1) Gene in Pancreatic Adenocarcinoma. Nature Genetics, 8, 27-32.
http://dx.doi.org/10.1038/ng0994-27

[11]   Liu, T.J., Niu, Y., Feng, Y.M., Niu, R.F., Yu, Y., Lv, A., et al. (2008) Methylation of CpG Islands of p16INK4a and cyclinD1 Overexpression Associated with Progression of Intraductal Proliferative Lesions of the Breast. Human Pathology, 39, 1637-1646.
http://dx.doi.org/10.1016/j.humpath.2008.04.001

[12]   Asamoto, M., Iwahori, Y., Okamura, T., Shirai, T. and Tsuda, H. (1997) Decreased Expression of the p16/MTS1 Gene without Mutation Is Frequent in Human Urinary Bladder Carcinomas. Japanese Journal of Clinical Oncology, 27, 22-25.
http://dx.doi.org/10.1093/jjco/27.1.22

[13]   Kawaguchi, K., Oda, Y., Saito, T., Yamamoto, H., Tamiya, S., Takahira, T., et al. (2003) Mechanisms of Inactivation of the p16INK4a Gene in Leiomyosarcoma of Soft Tissue: Decreased p16 Expression Correlates with Promoter Methylation and Poor Prognosis. The Journal of Pathology, 201, 487-495.
http://dx.doi.org/10.1002/path.1419

[14]   Surowiak, P., Materna, V., Maciejczyk, A., Pudelko, M., Suchocki, S., Kedzia, W., et al. (2008) Decreased Expression of p16 in Ovarian Cancers Represents an Unfavourable Prognostic Factor. Histology and Histopathology, 23, 531-538.

[15]   Lesnikova, I., Lidang, M., Hamilton-Dutoit, S. and Koch, J. (2009) p16 as a Diagnostic Marker of Cervical Neoplasia: A Tissue Microarray Study of 796 Archival Specimens. Diagnostic Pathology, 4, 22.
http://dx.doi.org/10.1186/1746-1596-4-22

[16]   Branca, M., Ciotti, M., Santini, D., Di Bonito, L., Giorgi, C., Benedetto, A., et al. (2004) p16INK4A Expression Is Related to Grade of CIN and High-Risk Human Papillomavirus but Does Not Predict Virus Clearance after Conization or Disease Outcome. International Journal of Gynecological Pathology, 23, 354-365.
http://dx.doi.org/10.1097/01.pgp.0000139639.79105.40

[17]   Reuschenbach, M., Vinokurova, S. and von Knebel Doeberitz, M. (2011) HPV-Associated Carcinomas of the Female Genital Tract. Molecular Mechanisms of Development. Der Pathologe, 32, 451-460.
http://dx.doi.org/10.1007/s00292-011-1474-7

[18]   Yemelyanova, A., Ji, H., Shih, I.M., Wang, T.L., Wu, L.S. and Ronnett, B.M. (2009) Utility of p16 Expression for Distinction of Uterine Serous Carcinomas from Endometrial Endometrioid and Endocervical Adenocarcinomas: Immunohistochemical Analysis of 201 Cases. American Journal of Surgical Pathology, 33, 1504-1514.
http://dx.doi.org/10.1097/PAS.0b013e3181ac35f5

[19]   Bodner-Adler, B., Bodner, K., Czerwenka, K., Kimberger, O., Leodolter, S. and Mayerhofer, K. (2005) Expression of p16 Protein in Patients with Uterine Smooth Muscle Tumors: An Immunohistochemical Analysis. Gynecologic Oncology, 96, 62-66.
http://dx.doi.org/10.1016/j.ygyno.2004.09.026

[20]   Atkins, K.A., Arronte, N., Darus, C.J. and Rice, L.W. (2008) The Use of p16 in Enhancing the Histologic Classification of Uterine Smooth Muscle Tumors. American Journal of Surgical Pathology, 32, 98-102.
http://dx.doi.org/10.1097/PAS.0b013e3181574d1e

[21]   O’Neill, C.J., McBride, H.A., Connolly, L.E. and McCluggage, W.G. (2007) Uterine Leiomyosarcomas Are Characterized by High p16, p53 and MIB1 Expression in Comparison with Usual Leiomyomas, Leiomyoma Variants and Smooth Muscle Tumours of Uncertain Malignant Potential. Histopathology, 50, 851-858.
http://dx.doi.org/10.1111/j.1365-2559.2007.02699.x

[22]   Zhao, W., Huang, C.C., Otterson, G.A., Leon, M.E., Tang, Y., Shilo, K., et al. (2012) Altered p16INK4 and RB1 Expressions Are Associated with Poor Prognosis in Patients with Non-Small Cell Lung Cancer. Journal of Oncology, 2012, Article ID: 957437.
http://dx.doi.org/10.1155/2012/957437

[23]   Reed, J.A., Loganzo Jr., F., Shea, C.R., Walker, G.J., Flores, J.F., Glendening, J.M., et al. (1995) Loss of Expression of the p16/Cyclin-Dependent Kinase Inhibitor 2 Tumor Suppressor Gene in Melanocytic Lesions Correlates with Invasive Stage of Tumor Progression. Cancer Research, 55, 2713-2718.

[24]   Bartsch, D., Shevlin, D.W., Callery, M.P., Norton, J.A., Wells Jr., S.A. and Goodfellow, P.J. (1996) Reduced Survival in Patients with Ductal Pancreatic Adenocarcinoma Associated with CDKN2 Mutation. Journal of the National Cancer Institute, 88, 680-682.
http://dx.doi.org/10.1093/jnci/88.10.680

[25]   Murai, Y., Hayashi, S., Takahashi, H., Tsuneyama, K. and Takano, Y. (2005) Correlation between DNA Alterations and p53 and p16 Protein Expression in Cancer Cell Lines. Pathology—Research and Practice, 201, 109-115.
http://dx.doi.org/10.1016/j.prp.2005.01.002

[26]   Wang, P., Pei, R.G., Lu, Z.M., Rao, X.S. and Liu, B.G. (2013) Methylation of p16 CpG Islands Correlated with Metastasis and Aggressiveness in Papillary Thyroid Carcinoma. Journal of the Chinese Medical Association, 76, 135-139.
http://dx.doi.org/10.1016/j.jcma.2012.11.007

[27]   Bartoletti, R., Cai, T., Nesi, G., Roberta Girardi, L., Baroni, G. and Dal Canto, M. (2007) Loss of P16 Expression and Chromosome 9p21 LOH in Predicting Outcome of Patients Affected by Superficial Bladder Cancer. Journal of Surgical Research, 143, 422-427.
http://dx.doi.org/10.1016/j.jss.2007.01.012

[28]   Duncan, L.D., Winkler, M., Carlson, E.R., Heidel, R.E., Kang, E. and Webb, D. (2013) p16 Immunohistochemistry Can Be Used to Detect Human Papillomavirus in Oral Cavity Squamous Cell Carcinoma. Journal of Oral and Maxillofacial Surgery, 71, 1367-1375.
http://dx.doi.org/10.1016/j.joms.2013.02.019

[29]   Milde-Langosch, K., Bamberger, A.M., Rieck, G., Kelp, B. and Loning, T. (2001) Overexpression of the p16 Cell Cycle Inhibitor in Breast Cancer Is Associated with a More Malignant Phenotype. Breast Cancer Research and Treatment, 67, 61-70.
http://dx.doi.org/10.1023/A:1010623308275

[30]   ünver, N.U., Acikalin, M.F., Oner, U., Ciftci, E., Ozalp, S.S. and Colak, E. (2011) Differential Expression of P16 and P21 in Benign and Malignant Uterine Smooth Muscle Tumors. Archives of Gynecology and Obstetrics, 284, 483-490.
http://dx.doi.org/10.1007/s00404-010-1690-z

[31]   Ip, P.P., Cheung, A.N. and Clement, P.B. (2009) Uterine Smooth Muscle Tumors of Uncertain Malignant Potential (STUMP): A Clinicopathologic Analysis of 16 Cases. American Journal of Surgical Pathology, 33, 992-1005.
http://dx.doi.org/10.1097/PAS.0b013e3181a02d1c

[32]   Huang, L.W. and Lee, C.C. (2012) P16INK4A Overexpression Predicts Lymph Node Metastasis in Cervical Carcinomas. Journal of Clinical Pathology, 65, 117-121.
http://dx.doi.org/10.1136/jclinpath-2011-200362

[33]   Rischin, D., Young, R.J., Fisher, R., Fox, S.B., Le, Q.T., Peters, L.J., et al. (2010) Prognostic Significance of p16INK4A and Human Papillomavirus in Patients with Oropharyngeal Cancer Treated on TROG 02.02 Phase III Trial. Journal of Clinical Oncology, 28, 4142-4148.
http://dx.doi.org/10.1200/JCO.2010.29.2904

[34]   Lau, H.Y., Brar, S., Klimowicz, A.C., Petrillo, S.K., Hao, D., Brockton, N.T., et al. (2011) Prognostic Significance of p16 in Locally Advanced Squamous Cell Carcinoma of the Head and Neck Treated with Concurrent Cisplatin and Radiotherapy. Head & Neck, 33, 251-256.
http://dx.doi.org/10.1002/hed.21439

[35]   Schwarz, J.K., Lewis Jr., J.S., Pfeifer, J., Huettner, P. and Grigsby, P. (2012) Prognostic Significance of p16 Expression in Advanced Cervical Cancer Treated with Definitive Radiotherapy. International Journal of Radiation Oncology, Biology, Physics, 84, 153-157.
http://dx.doi.org/10.1016/j.ijrobp.2011.11.032

 
 
Top